American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3388-3404

  Gilligan, Timothy D ^a   Seidenfeld, Jerome ^a   Basch, Ethan M ^a   Einhorn, Lawrence H ^a   Fancher, Timothy ^a   Smith, David C ^a   Stephenson, Andrew J ^a   Vaughn, David J ^a   Cosby, Roxanne ^a   Hayes, Daniel F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; LACTATE DEHYDROGENASE; TUMOR MARKER;

ADULT; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SCREENING; CANCER SURGERY; DIAGNOSTIC ACCURACY; EMBASE; EVIDENCE BASED PRACTICE; FALSE POSITIVE RESULT; GERM CELL TUMOR; HUMAN; MALE; MEDICAL SOCIETY; MEDLINE; ONCOLOGY; ORCHIECTOMY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SEMINOMA; SYSTEMATIC REVIEW; ARTICLE; BLOOD; CANCER OF UNKNOWN PRIMARY SITE; DECISION MAKING; MEDIASTINUM TUMOR; NEOPLASM; RETROPERITONEAL TUMOR; TESTIS TUMOR;

ADULT; DECISION MAKING; HUMANS; MALE; MEDIASTINAL NEOPLASMS; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, UNKNOWN PRIMARY; ORCHIECTOMY; RETROPERITONEAL NEOPLASMS; SEMINOMA; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954695955     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.4481     Document Type: Review

References (172)

1. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
2. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327, 2006
3. Feldman DR, Bosl GJ, Sheinfeld J, et al: Medical treatment of advanced testicular cancer. JAMA 299:672-684, 2008 (Pubitemid 351252727)
4. McKenney JK, Heerema-McKenney A, Rouse RV: Extragonadal germ cell tumors: A review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol 14:69-92, 2007 (Pubitemid 46673283)
5. Krege S, Beyer J, Souchon R, et al: European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG) - Part I. Eur Urol 53:478-496, 2008
6. Motzer RJ, Agarwal N, Beard C, et al: NCCN clinical practice guidelines in oncology: Testicular cancer. J Natl Compr Canc Netw 7:672-693, 2009
7. Krege S, Beyer J, Souchon R, et al: European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG) - Part II. Eur Urol 53:497-513, 2008
8. Schmoll HJ, Jordan K, Huddart R, et al: Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:89-96, 2009 (suppl 4)
9. Schmoll HJ, Jordan K, Huddart R, et al: Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:83-88, 2009 (suppl 4)
10. Marcillac I, Troalen F, Bidart JM, et al: Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res 52:3901-3907, 1992
11. Stenman UH, Alfthan H, Hotakainen K: Human chorionic gonadotropin in cancer. Clin Biochem 37:549-561, 2004 (Pubitemid 38845018)
12. Cole LA: New discoveries on the biology and detection of human chorionic gonadotropin. Reprod Biol Endocrinol 7:8, 2009
13. Okunaka T, Kato H, Konaka C, et al: Primary lung cancer producing alpha-fetoprotein. Ann Thorac Surg 53:151-152, 1992
14. Adachi Y, Tsuchihashi J, Shiraishi N, et al: AFP-producing gastric carcinoma: Multivariate analysis of prognostic factors in 270 patients. Oncology 65:95-101, 2003 (Pubitemid 37025967)
15. Yachida S, Fukushima N, Nakanishi Y, et al: Alpha-fetoprotein-producing carcinoma of the colon: Report of a case and review of the literature. Dis Colon Rectum 46:826-831, 2003 (Pubitemid 36693404)
16. Staples J: Alphafetoprotein, cancer, and benign conditions. Lancet 2:1277, 1986
17. Schefer H, Mattmann S, Joss RA: Hereditary persistence of alpha-fetoprotein. Case report and review of the literature. Ann Oncol 9:667-672, 1998
18. Li X, Alexander S: Hereditary persistence of alpha-fetoprotein. Pediatr Blood Cancer 52:403-405, 2009
19. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002, pp 469,
20. Sobin LH, Wittekind C (eds): International Union Against Cancer: TNM - Classification of Malignant Tumors. New York, NY, Wiley-Liss, 2002, pp 239
21. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers - International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
22. Albers P, Albrecht W, Algaba F, et al: European Association of Urology (EAU) Guidelines on Testicular Cancer, 2009
23. Sturgeon CM, Duffy MJ, Stenman UH, et al: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54:e11-e79, 2008 (Pubitemid 352777353)
24. Chung P, Mayhew LA, Warde P, et al: Management of Stage I Seminoma: Guideline Recommendations, Cancer Care Ontario Program in Evidence-Based Care, 2008, pp 1-34
25. Hotte S, Mayhew LA, Jewett M, et al: Management of Stage I Nonseminomatous Testicular Cancer: Guideline Recommendations, Cancer Care Ontario Program in Evidence-Based Care, 2008, pp 1-30
26. van As NJ, Gilbert DC, Money-Kyrle J, et al: Evidence-based pragmatic guidelines for the follow-up of testicular cancer: Optimising the detection of relapse. Br J Cancer 98:1894-1902, 2008
27. Li MC: Trophoblastic disease: Natural history, diagnosis, and treatment. Ann Intern Med 74:102-112, 1971
28. Rosen SW, Weintraub BD, Vaitukaitis JL, et al: Placental proteins and their subunits as tumor markers. Ann Intern Med 82:71-83, 1975
29. Braunstein GD, McIntire KR, Waldmann TA: Discordance of human chorionic gonadotropin and alpha-fetoprotein in testicular teratocarcinomas. Cancer 31:1065-1068, 1973
30. Lange PH, McIntire KR, Waldmann TA, et al: Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. N Engl J Med 295:1237-1240, 1976
31. Javadpour N, McIntire KR, Waldmann TA: Human chorionic gonadotropin (hCG) and alphafetoprotein (AFP) in sera and tumor cells of patients with testicular seminoma: A prospective study. Cancer 42:2768-2772, 1978 (Pubitemid 9095051)
32. Schultz H, Sell A, Norgaard-Pedersen B, et al: Serum alpha-fetoprotein and human chorionic gonadotropin as markers for the effect of postoperative radiation therapy and/or chemotherapy in testicular cancer. Cancer 42:2182-2186, 1978 (Pubitemid 9125873)
33. Javadpour N, McIntire KR, Waldmann TA: Immunochemical determination of human chorionic gonadotropin and alpha-fetoprotein in sera and tumors of patients with testicular cancer. Natl Cancer Inst Monogr 1978, 209-213 (Pubitemid 9141835)
34. Lange PH, Nochomovitz LE, Rosai J, et al: Serum alpha-fetoprotein and human chorionic gonadotropin in patients with seminoma. J Urol 124:472-478, 1980 (Pubitemid 10030175)
35. von Eyben FE: Biochemical markers in advanced testicular tumors: Serum lactate dehydrogenase, urinary chorionic gonadotropin and total urinary estrogens. Cancer 41:648-652, 1978
36. Lippert M, Papadopoulos N, Javadpour N: Role of lactate dehydrogenase isoenzymes in testicular cancer. Urology 18:50-53, 1981 (Pubitemid 11083361)
37. Lippert MC, Javadpour N: Lactic dehydrogenase in the monitoring and prognosis of testicular cancer. Cancer 48:2274-2278, 1981 (Pubitemid 12231602)
38. von Eyben FE, Skude G, Fossa SD, et al: Serum lactate dehydrogenase (S-LDH) and S-LDH isoenzymes in patients with testicular germ cell tumors. Mol Gen Genet 189:326-333, 1983 (Pubitemid 13136198)
39. von Eyben FE: Lactate dehydrogenase and its isoenzymes in testicular germ cell tumors: An overview. Oncodev Biol Med 4:395-414, 1983
40. Perlin E, Engeler JE Jr, Edson M, et al: The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. Cancer 37:215-219, 1976
41. Thompson DK, Haddow JE: Serial monitoring of serum alpha-fetoprotein and chorionic gonadotropin in males with germ cell tumors. Cancer 43:1820-1829, 1979
42. Germa-Lluch JR, Begent RH, Bagshawe KD: Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer 42:850-855, 1980 (Pubitemid 11199284)
43. Bosl GJ, Geller NL, Cirrincione C, et al: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403-3407, 1983 (Pubitemid 13061604)
44. Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986 (Pubitemid 16133094)
45. Hoskin P, Dilly S, Easton D, et al: Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: Implications for adjuvant chemotherapy. J Clin Oncol 4:1031-1036, 1986 (Pubitemid 16059729)
46. Javadpour N: Biologic tumor markers in management of testicular and bladder cancer. Urology 12:177-183, 1978
47. Bajorin DF, Bosl GJ: The use of serum tumor markers in the prognosis and treatment of germ cell tumors. PPO Updates 6:1-11, 1992
48. Javadpour N: Current status of tumor markers in testicular cancer: A practical review. Eur Urol 21:34-36, 1992 (suppl 1)
49. Klein EA: Tumor markers in testis cancer. Urol Clin North Am 20:67-73, 1993
50. von Eyben FE: A systematic review of lactate dehydrogenase isoenzyme 1 and germ cell tumors. Clin Biochem 34:441-454, 2001
51. Kurman RJ, Scardino PT, McIntire KR, et al: Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique. Cancer 40:2136-2151, 1977 (Pubitemid 8239703)
52. Jacobsen GK, Jacobsen M: Alphafetoprotein (AFP) and human chorionic gonadotropin (hCG) in testicular germ cell tumours: A prospective immunohistochemical study. Acta Pathol Microbiol Immunol Scand A 91:165-176, 1983 (Pubitemid 13094889)
53. Jacobsen GK: Alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) in testicular germ cell tumours: A comparison of histologic and serologic occurrence of tumour markers. Acta Pathol Microbiol Immunol Scand A 91:183-190, 1983
54. Morinaga S, Ojima M, Sasano N: Human chorionic gonadotropin and alpha-fetoprotein in testicular germ cell tumors. An immunohistochemical study in comparison with tissue concentrations. Cancer 52:1281-1289, 1983
55. Butcher DN, Gregory WM, Gunter PA, et al: The biological and clinical significance of hCG-containing cells in seminoma. Br J Cancer 51:473-478, 1985 (Pubitemid 15087084)
56. Lange PH, Vogelzang NJ, Goldman A, et al: Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 128:708-711, 1982 (Pubitemid 13236336)
57. Toner GC, Geller NL, Tan C, et al: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50:5904-5910, 1990 (Pubitemid 20331398)
58. Stevens MJ, Norman AR, Dearnaley DP, et al: Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 13:87-92, 1995
59. de Wit R, Sylvester R, Tsitsa C, et al: Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: A study in patients with disseminated non-seminomatous testicular cancer. Br J Cancer 75:432-435, 1997 (Pubitemid 27051062)
60. Gerl A, Lamerz R, Mann K, et al: Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors? Anticancer Res 17:3047-3049, 1997
61. Mazumdar M, Bajorin DF, Bacik J, et al: Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19:2534-2541, 2001 (Pubitemid 32391225)
62. Fizazi K, Culine S, Kramar A, et al: Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22:3868-3876, 2004 (Pubitemid 41079867)
63. Kalinski T, Roessner A: Hepatocellular carcinoma: Pathology and liver biopsy. Dig Dis 27:102-108, 2009
64. Hussain K, El-Serag HB: Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol 55:123-138, 2009
65. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
66. Nazeer T, Ro JY, Amato RJ, et al: Histologically pure seminoma with elevated alpha-fetoprotein: A clinicopathologic study of ten cases. Oncol Rep 5:1425-1429, 1998 (Pubitemid 28474088)
67. Scardino PT, Cox HD, Waldmann TA, et al: The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. J Urol 118:994-999, 1977 (Pubitemid 8261174)
68. Karanikolas NT, Secin FP, Stasi J, et al: Non-seminomatous retroperitoneal histology in patients with a pure testicular seminoma and an elevated serum alpha feto-protein. J Clin Oncol 24:641s, 2006 (suppl; abstr 14561)
69. Davis BE, Herr HW, Fair WR, et al: The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 152:111-113, 1994
70. Saxman SB, Nichols CR, Foster RS, et al: The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol 155:587-589, 1996 (Pubitemid 26023549)
71. Stephenson AJ, Bosl GJ, Motzer RJ, et al: Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: Impact of patient selection factors on outcome. J Clin Oncol 23:2781-2788, 2005 (Pubitemid 46179468)
72. Hainsworth JD, Johnson DH, Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J Clin Oncol 10:912-922, 1992
73. Pavlidis N, Kalef-Ezra J, Briassoulis E, et al: Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 22:162-167, 1994 (Pubitemid 24054761)
74. Lenzi R, Hess KR, Abbruzzese MC, et al: Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 15:2056-2066, 1997
75. Pouessel D, Thezenas S, Culine S, et al: Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol 29:1224-1232, 2005
76. Yonemori K, Ando M, Shibata T, et al: Tumormarker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Cancer Res Clin Oncol 132:635-642, 2006 (Pubitemid 44310329)
77. Carpelan-Holmström M, Haglund C, Lundin J, et al: Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer 74:925-929, 1996 (Pubitemid 26319326)
78. Louhimo J, Kokkola A, Alfthan H, et al: Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer. Int J Cancer 111:929-933, 2004 (Pubitemid 39096242)
79. Hurley LJ, Burke CR, Shetty SK, et al: Elevated alpha-fetoprotein secondary to Hodgkin's lymphoma. Urology 48:936-938, 1996 (Pubitemid 26427106)
80. Fraternali-Orcioni G, Falini B, Quaini F, et al: Beta-hCG aberrant expression in primary mediastinal large B-cell lymphoma. Am J Surg Pathol 23:717-721, 1999 (Pubitemid 29262836)
81. Leong MY, English M, McMullan D, et al: Aberrant expression of beta-hCG in anaplastic large cell lymphoma. Pediatr Dev Pathol 11:230-234, 2008
82. Aass N, Fosså SD, Ous S, et al: Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage nonseminomatous testicular cancer? Br J Urol 65:385-390, 1990
83. Kulkarni JN, Kamat MR: Value of tumor markers in nonseminomatous germ cell tumor of the testis. Eur Urol 24:166-171, 1993 (Pubitemid 23246041)
84. Rabbani F, Sheinfeld J, Farivar-Mohseni H, et al: Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse. J Clin Oncol 19:2020-2025, 2001 (Pubitemid 32702546)
85. Price P, Hogan SJ, Bliss JM, et al: The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time: II. Prognostic significance in patients treated by chemotherapy. Eur J Cancer 26:453-457, 1990 (Pubitemid 20209974)
86. Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 8:1683-1694, 1990 (Pubitemid 20334323)
87. Toner GC, Geller NL, Lin SY, et al: Extragonadal and poor risk nonseminomatous germ cell tumors: Survival and prognostic features. Cancer 67:2049-2057, 1991
88. Aass N, Klepp O, Cavallin-Stahl E, et al: Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: A multicenter experience. J Clin Oncol 9:818-826, 1991
89. Mead GM, Stenning SP, Parkinson MC, et al: The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors: Medical Research Council Testicular Tumour Working Party. J Clin Oncol 10:85-94, 1992
90. Jensen JL, Venner PM: Predictive factors for outcome in treatment of metastatic nonseminomatous germ cell tumors. Urology 39:237-242, 1992
91. Fosså SD, Qvist H, Stenwig AE, et al: Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 10:569-573, 1992
92. Gerl A, Clemm C, Lamerz R, et al: Prognostic implications of tumour marker analysis in nonseminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer 29:961-965, 1993 (Pubitemid 23126692)
93. Stoter G, Sleijfer D, Kaye SB, et al: Prognostic factors in metastatic non-seminomatous germ cell tumours: An interim analysis of the EORTC GU-Group experience. Eur Urol 23:202-206, 1993 (Pubitemid 23103484)
94. Steyerberg EW, Keizer HJ, Zwartendijk J, et al: Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: A multivariate analysis. Br J Cancer 68:195-200, 1993 (Pubitemid 23178578)
95. Kawakita M, Terachi T, Hida S, et al: Survival and prognostic factors associated with metastatic nonseminomatous testicular and extragonadal germ cell tumors. Int J Urol 1:172-176, 1994 (Pubitemid 2119538)
96. Steyerberg EW, Keizer HJ, Fosså SD, et al: Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J Clin Oncol 13:1177-1187, 1995
97. Hartmann JT, Schmoll HJ, Kuczyk MA, et al: Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 8:531-538, 1997
98. Steyerberg EW, Gerl A, Fosså SD, et al: Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16:269-274, 1998 (Pubitemid 28041608)
99. Steyerberg EW, Keizer HJ, Sleijfer DT, et al: Retroperitoneal metastases in testicular cancer: Role of CT measurements of residual masses in decision making for resection after chemotherapy. Radiology 215:437-444, 2000 (Pubitemid 30237842)
100. Kollmannsberger C, Nichols C, Meisner C, et al: Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: An explorative analysis using cart modeling. Ann Oncol 11:1115-1120, 2000
101. Vergouwe Y, Steyerberg EW, Foster RS, et al: Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J Urol 165:84-88, 2001
102. Hartmann JT, Nichols CR, Droz JP, et al: Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 13:1017-1028, 2002
103. Kesler KA, Brooks JA, Rieger KM, et al: Mediastinal metastases from testicular nonseminomatous germ cell tumors: Patterns of dissemination and predictors of long-term survival with surgery. J Thorac Cardiovasc Surg 125:913-923, 2003 (Pubitemid 36457514)
104. van Dijk MR, Steyerberg EW, Stenning SP, et al: Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modeling: A validation study. Ann Oncol 15:1400-1405, 2004 (Pubitemid 39295028)
105. Vergouwe Y, Steyerberg EW, Foster RS, et al: Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: A model update and multicentre validation with more than 1000 patients. Eur Urol 51:424-432, 2007 (Pubitemid 44937791)
106. Steyerberg EW, Keizer HJ, Stoter G, et al: Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: A quantitative overview of 996 resections. Eur J Cancer 30A:1231-1239, 1994 (Pubitemid 24322053)
107. Bloomer JR, Waldmann TA, McIntire KR, et al: Alpha-fetoprotein in noneoplastic hepatic disorders. JAMA 233:38-41, 1975
108. Germà JR, Llanos M, Tabernero JM, et al: False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer 72:2491-2494, 1993 (Pubitemid 23299616)
109. Garnick MB: Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer. N Engl J Med 303:1177, 1980
110. Morris MJ, Bosl GJ: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol 163:796-801, 2000 (Pubitemid 30091619)
111. Bokemeyer C, Nichols CR, Droz JP, et al: Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis. J Clin Oncol 20:1864-1873, 2002
112. Bokemeyer C, Hartmann JT, Fossa SD, et al: Extragonadal germ cell tumors: Relation to testicular neoplasia and management options. APMIS 111:49-59, 2003; discussion 59-63
113. Hartmann JT, Einhorn L, Nichols CR, et al: Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis. J Clin Oncol 19:1641-1648, 2001 (Pubitemid 32230863)
114. Culine S, Kerbrat P, Kramar A, et al: Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: A randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18:917-924, 2007 (Pubitemid 47054091)
115. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987 (Pubitemid 17079090)
116. Bosl GJ, Geller NL, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231-1238, 1988
117. Nichols CR, Catalano PJ, Crawford ED, et al: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16:1287-1293, 1998 (Pubitemid 28175741)
118. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989 (Pubitemid 19075021)
119. Saxman SB, Finch D, Gonin R, et al: Longterm follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indian University experience. J Clin Oncol 16:702-706, 1998 (Pubitemid 28135618)
120. de Wit R, Roberts JT, Wilkinson PM, et al: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001 (Pubitemid 32230862)
121. de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular nonseminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group - European Organization for Research and Treatment of Cancer. Br J Cancer 78:828-832, 1998 (Pubitemid 28418322)
122. Motzer RJ, Nichols CJ, Margolin KA, et al: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247-256, 2007 (Pubitemid 350003012)
123. de Wit R, Collette L, Sylvester R, et al: Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 78:1350-1355, 1998 (Pubitemid 28495249)
124. Ravi R, Ong J, Oliver RT, et al: Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol 81:884-888, 1998 (Pubitemid 28300621)
125. Beck SD, Foster RS, Bihrle R, et al: Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 23:6149-6156, 2005
126. Kobayashi T, Kawakita M, Terachi T, et al: Significance of elevated preoperative alphafetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors. J Surg Oncol 94:619-623, 2006 (Pubitemid 44851924)
127. Spiess PE, Brown GA, Liu P, et al: Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107:1483-1490, 2006 (Pubitemid 44546907)
128. Shayegan B, Carver BS, Stasi J, et al: Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU Int 99:993-997, 2007 (Pubitemid 46587905)
129. Kesler KA, Rieger KM, Hammoud ZT, et al: A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg 85:371-378, 2008
130. Albers P, Ganz A, Hannig E, et al: Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164:381-384, 2000 (Pubitemid 30481930)
131. Fosså SD, Stenning SP, Gerl A, et al: Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant nonseminomatous germ cell tumours. Br J Cancer 80:1392-1399, 1999 (Pubitemid 29308608)
132. Beyer J, Stenning S, Gerl A, et al: Highdose versus conventional-dose chemotherapy as first-salvage treatment in patients with nonseminomatous germ-cell tumors: A matched-pair analysis. Ann Oncol 13:599-605, 2002 (Pubitemid 34461144)
133. Gels ME, Hoekstra HJ, Sleijfer DT, et al: Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: A single-center 10-year experience. J Clin Oncol 13:1188-1194, 1995
134. Seckl MJ, Rustin GJ, Bagshawe KD: Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours. Br J Cancer 61:916-918, 1990 (Pubitemid 20197005)
135. Nikzas D, Champion AE, Fox M: Germ cell tumours of testis: Prognostic factors and results. Eur Urol 18:242-247, 1990
136. Kausitz J, Ondrus D, Belan V, et al: Monitoring of patients with non-seminomatous germ cell tumors of the testis by determination of alphafetoprotein and beta-human chorionic gonadotropin levels and by computed tomography. Neoplasma 39:357-361, 1992 (Pubitemid 23010816)
137. Trigo JM, Tabernero JM, Paz-Ares L, et al: Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 88:162-168, 2000 (Pubitemid 30027692)
138. von Eyben FE, Madsen EL, Blaabjerg O, et al: Serum lactate dehydrogenase isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage I. Acta Oncol 40:536-540, 2001 (Pubitemid 32682039)
139. Daugaard G, Petersen PM, Rørth M: Surveillance in stage I testicular cancer. APMIS 111:76-83, 2003
140. Divrik RT, Akdoǧan B, Ozen H, et al: Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors: Is shift to risk adapted policy justified? J Urol 176:1424-1430, 2006 (Pubitemid 44307195)
141. Ackers C, Rustin GJ: Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours. Br J Cancer 94:1231-1232, 2006
142. Venkitaraman R, Johnson B, Huddart RA, et al: The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int 100:30-32, 2007 (Pubitemid 46878559)
143. George DW, Foster RS, Hromas RA, et al: Update on late relapse of germ cell tumor: A clinical and molecular analysis. J Clin Oncol 21:113-122, 2003
144. Dieckmann KP, Albers P, Classen J, et al: Late relapse of testicular germ cell neoplasms: A descriptive analysis of 122 cases. J Urol 173:824-829, 2005 (Pubitemid 40239350)
145. Oldenburg J, Alfsen GC, Waehre H, et al: Late recurrences of germ cell malignancies: A population-based experience over three decades. Br J Cancer 94:820-827, 2006
146. Sharp DS, Carver BS, Eggener SE, et al: Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 26:5524-5529, 2008
147. Oldenburg J, Martin JM, and Fosså SD: Late relapses of germ cell malignancies: Incidence, management, and prognosis. J Clin Oncol 24:5503-5511, 2006 (Pubitemid 46631330)
148. Mencel PJ, Motzer RJ, Mazumdar M, et al: Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12:120-126, 1994
149. Fosså SD, Oliver RT, Stenning SP, et al: Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 33:1380-1387, 1997 (Pubitemid 27404894)
150. Bokemeyer C, Droz JP, Horwich A, et al: Extragonadal seminoma: An international multicenter analysis of prognostic factors and long term treatment outcome. Cancer 91:1394-1401, 2001 (Pubitemid 32267053)
151. Gholam D, Fizazi K, Terrier-Lacombe MJ, et al: Advanced seminoma: Treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease - A single-institution experience in 145 patients. Cancer 98:745-752, 2003 (Pubitemid 36959270)
152. Miller KD, Loehrer PJ, Gonin R, et al: Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15:1427-1431, 1997 (Pubitemid 27167375)
153. Vuky J, Tickoo SK, Sheinfeld J, et al: Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 20:297-301, 2002 (Pubitemid 34032624)
154. Fosså SD, Horwich A, Russell JM, et al: Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial - Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17:1146, 1999
155. Jones WG, Fossa SD, Mead GM, et al: Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23:1200-1208, 2005 (Pubitemid 46202277)
156. Oliver RT, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: A randomised trial. Lancet 366:293-300, 2005 (Pubitemid 41019418)
157. Warde PR, Gospodarowicz MK, Goodman PJ, et al: Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 27:11-15, 1993 (Pubitemid 23270651)
158. Warde P, Gospodarowicz MK, Panzarella T, et al: Stage I testicular seminoma: Results of adjuvant irradiation and surveillance. J Clin Oncol 13:2255-2262, 1995
159. Choo R, Thomas G, Woo T, et al: Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. Int J Radiat Oncol Biol Phys 61:736-740, 2005 (Pubitemid 40247967)
160. Aparicio J, García del Muro X, Maroto P, et al: Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14:867-872, 2003 (Pubitemid 36827202)
161. Aparicio J, Germà JR, García del Muro X, et al: Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23:8717-8723, 2005 (Pubitemid 46211516)
162. Ramakrishnan S, Champion AE, Dorreen MS, et al: Stage I seminoma of the testis: Is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin Oncol (R Coll Radiol) 4:284-286, 1992
163. Livsey JE, Taylor B, Mobarek N, et al: Patterns of relapse following radiotherapy for stage I seminoma of the testis: Implications for follow-up. Clin Oncol (R Coll Radiol) 13:296-300, 2001
164. Chung P, Parker C, Panzarella T, et al: Surveillance in stage I testicular seminoma: Risk of late relapse. Can J Urol 9:1637-1640, 2002
165. Munro AJ, Nielsen OS, Duncan W, et al: An assessment of combined tumour markers in patients with seminoma: Placental alkaline phosphatase (PLAP), lactate dehydrogenase (LD) and beta human chorionic gonadotrophin (beta hCG). Br J Cancer 64:537-542, 1991
166. Horwich A, Alsanjari N, A'Hern R, et al: Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65:775-778, 1992
167. Coleman JM, Coleman RE, Turner AR, et al: The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin Oncol (R Coll Radiol) 10:237-241, 1998 (Pubitemid 28454543)
168. Mead H, Cartwright-Smith L, Jones K, et al: Racial and ethnic disparities in U.S. health care: A chartbook. The Commonwealth Fund, March 2008
169. U.S. Cancer Statistics Working Group: United States Cancer Statistics: 1999-2002 Incidence and Mortality Web-based Report. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2005
170. Ries LAG, Eisner MP, Kossary CL, et al (eds): SEER Cancer Statistics Review: 1973-1997. Bethesda, MD, National Cancer Institute, 2000. http://seer.cancer.gov/csr/1975-2003/results-merged/topic-race-ethnicity.pdf
171. American Cancer Society: Cancer Facts and Figures for African Americans 2005-2006. Atlanta, GA, American Cancer Society, 2005
172. Horner MJ, Ries LAG, et al (eds): SEER Cancer Statistics Review, 1975-2006. Bethesda, MD, National Cancer Institute, 2009